# p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer

> **NCT00844506** · PHASE2 · COMPLETED · sponsor: **University Medical Center Groningen** · enrollment: 19 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** P53-SLP vaccine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00844506
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2011-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00844506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00844506, "p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00844506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*